You are here: Industry Insights > Daiichi

News List

Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML drugs
April 17, 2019
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML.
Daiichi gets speedy FDA review for rare cancer drug pharmaphorum
February 14, 2019
Daiichi Sankyo has been given a priority review from the FDA for pexidartinib, which is vying to become the first systemic drug therapy for rare cancer tenosynovial giant cell tumour (TGCT)....
Roivant strikes broad pipeline pact with Daiichi fiercebiotech
December 25, 2018
Roivant has secured an option to license a stream of drugs from Daiichi Sankyo. The deal is the first time Roivant has formed a framework to facilitate the ongoing in-licensing of drugs from a company rather than picked up assets on an ad hoc basis.....
Daiichi to test cancer drug combo pharmatimes
September 21, 2018
Daiichi Sankyo has entered into a clinical trial collaboration agreement with a subsidiary of MSD to evaluate a potential new combination therapy for breast or lung cancers.
Daiichi Sankyo to develop new inflammatory disease drugs pharmaceutical-technology
June 01, 2018
Daiichi Sankyo has formed a new consortium focused on research and discovery of medicines over a period of five years to treat intractable immune-mediated inflammatory diseases.
Thermo Fisher inks deals with Daiichi and Takeda biospectrumasia
May 03, 2018
Thermo Fisher Scientific has entered into agreements with Daiichi Sankyo and Takeda Pharmaceutical aimed at expanding the utility of its Oncomine Dx Target Test to support each firm's clinical trials and development programs.

Previous page 1 2 Next page